Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer

• Status: Completed
• Trial end date: 2020-03-15
• Target enrollment: 0
• Participant gender: All

Summary

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced colorectal cancer is not definite. The hypothesis of the trial is that radical colorectal resection plus HIPEC is superior to only radical colorectal resection in terms of overall survival.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan University
• Treatments: Albumin-Bound Paclitaxel; Capecitabine; Oxaliplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Histological proved diagnosis of locally advanced colorectal cancer.

• No evidence of distant metastases or peritoneal metastases.

• Preoperative examination (CT/MRI) demonstrated resectable colorectal cancer with T3-T4 stage.

• Eligible for radical colorectal resection with lymphadenectomy.

• Have not received cytotoxic chemotherapy or radiotherapy.

• Written informed consent is obtained prior to commencement of trial treatment.

Exclusion Criteria:

• Existence of distant metastasis or peritoneal metastasis during surgery (M1).

• Any previous chemotherapy or radiotherapy

• Active systemic infections

• Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.

• Female patients who are pregnant or breast feeding